IMMUNIC, INC. Files 8-K Report

Ticker: IMUX · Form: 8-K · Filed: Sep 10, 2024 · CIK: 1280776

Immunic, INC. 8-K Filing Summary
FieldDetail
CompanyImmunic, INC. (IMUX)
Form Type8-K
Filed DateSep 10, 2024
Risk Levellow
Pages4
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, compliance

TL;DR

IMMUNIC, INC. filed a routine 8-K with the SEC on Sept 10, 2024.

AI Summary

On September 10, 2024, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt.

Why It Matters

This filing indicates IMMUNIC, INC. is fulfilling its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report, indicating routine corporate compliance rather than a specific event with immediate high risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for IMMUNIC, INC.?

The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating routine SEC reporting.

When was the earliest event reported in this filing?

The earliest event reported was on September 10, 2024.

In which state is IMMUNIC, INC. incorporated?

IMMUNIC, INC. is incorporated in Delaware.

What is the principal executive office address for IMMUNIC, INC.?

The principal executive office is located at 1200 Avenue of the Americas, Suite 200, New York, NY 10036 USA.

Does this filing detail any specific new financial results or significant business developments?

The provided excerpt of the 8-K filing does not detail specific new financial results or significant business developments.

Filing Stats: 1,100 words · 4 min read · ~4 pages · Grade level 14.9 · Accepted 2024-09-10 16:05:53

Key Financial Figures

Filing Documents

01. Other Events

Item 8.01. Other Events. On September 10, 2024, Immunic, Inc. (the " Company ") hosted its multiple sclerosis research and development day (" R&D Day "), a scientific conference dedicated to certain multiple sclerosis-related therapeutic matters and aspects of vidofludimus calcium (IMU-838) in connection with the product candidate's future possible ability to treat relapsing and progressive multiple sclerosis patients, respectively. In the course of R&D Day, the Company presented certain information to attendees of R&D Day (the " Presentation "). A copy of the Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 8.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein. Cautionary Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K and the Presentation are "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this Current Report on Form 8-K and the Presentation regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases;

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit Description 99.1 Presentation, dated September 10, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: September 10, 2024 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing